StreetInsider.com News Articles

Form 4 Ocugen, Inc. For: Jun 15 Filed by: Johnson-Greene Treerita Essalima

Wed, 17 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660033.html

Form 4 Ocugen, Inc. For: Jun 15 Filed by: Johnson-Greene Treerita Essalima

Wed, 17 Jun 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260617/26660033.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Kompella Uday

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647956.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Kompella Uday

Mon, 15 Jun 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260615/26647956.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Chandrasekhar Satishchandran

Mon, 15 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260615/26647941.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Chandrasekhar Satishchandran

Mon, 15 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260615/26647941.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Castillo Kirsten

Mon, 15 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260615/26647921.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Castillo Kirsten

Mon, 15 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260615/26647921.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Coleman Blaise

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647865.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Coleman Blaise

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647865.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Zhang Junge

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647898.html

Form 4 Ocugen, Inc. For: Jun 11 Filed by: Zhang Junge

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647898.html

Form 8-K Ocugen, Inc. For: Jun 11

Thu, 11 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260611/26636805.html

Form 8-K Ocugen, Inc. For: Jun 11

Thu, 11 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260611/26636805.html

Form 8-K Ocugen, Inc. For: May 29

Wed, 03 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26599465.html

Form 8-K Ocugen, Inc. For: May 29

Wed, 03 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260603/26599465.html

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Tue, 02 Jun 2026 07:03:00 -0400

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026.

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39

Ocugen to Participate in Upcoming June Investor and Industry Conferences

Tue, 02 Jun 2026 07:03:00 -0400

Noble Capital Markets June 2026 Emerging Growth Virtual Equity Conference

Date: Thursday, June 4, 2026
Time: 2:30pm EDT

Clinical Trials at the Summit 2026

Location: Fontainebleau Las Vegas
Date: Saturday, June 13, 2026
Time: 10:19 – 10:39

Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord

Wed, 27 May 2026 06:55:19 -0400

(Updated - May 27, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $11.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "Last week we hosted a virtual NDR with OCGN management including Co-founder, Chairman and CEO Shankar Musunuri, Ph.D, MBA; CFO Rita Johnson-Greene, MBA; and CSO & Head of R&D Arun Upadhyay, Ph.D. Discussion focused on the upcoming blinded interim from the Ph2/3 study of OCU410ST in Stargardt disease, recent Ph2 data from OCU410 in geographic atrophy, and next trial design and BLA prep ahead of 1Q27 Ph3 data for

Ocugen, Inc. (OCGN) PT Lowered to $11 at Canaccord

Wed, 27 May 2026 06:55:19 -0400

(Updated - May 27, 2026 6:55 AM EDT)

Canaccord analyst Whitney Ijem lowered the price target on Ocugen, Inc. (NASDAQ: OCGN) to $11.00 (from $12.00) while maintaining a Buy rating.

Ocugen appoints new acting chief medical officer

Thu, 14 May 2026 16:41:47 -0400

Ocugen Inc. (NASDAQ: OCGN) announced leadership changes in its medical department. Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer effective May 8, 2026.

The company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer on the same date, according to the company's filing.

Ocugen appoints new acting chief medical officer

Thu, 14 May 2026 16:41:47 -0400

Ocugen Inc. (NASDAQ: OCGN) announced leadership changes in its medical department. Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer effective May 8, 2026.

The company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer on the same date, according to the company's filing.

Form 8-K Ocugen, Inc. For: May 08

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495776.html

Form 8-K Ocugen, Inc. For: May 08

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495776.html

Form 8-K Ocugen, Inc. For: May 14

Thu, 14 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260514/26495705.html